Saracatinib Trial TO Prevent FOP

Fibrodysplasia Ossificans Progressiva Clinical Trial

— STOPFOP  

Official title:

Saracatinib Trial TO Prevent FOP

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04307953
• Other study ID #: STOPFOP1
• Secondary ID: 2019-003324-20NL
• Status: Recruiting
• Phase: Phase 2
• Start date: August 5, 2020
• Est. completion date: May 6, 2025

Study information

• Verified date: April 2024
• Source: Amsterdam UMC, location VUmc
• Contact: Vincent A. Verheij, MD
• Phone: +31204444444
• Email: v.a.verheij[@]amsterdamumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data.

Study population: Male and female adult patients aged 18 years and older with a diagnosis of FOP who meet the inclusion (active disease) and exclusion criteria will be eligible for participation in this study. The total number of enrolled patients will be 20.

Intervention: Patients will be randomized to receive either AZD0530 100mg once daily or matched placebo, taken orally for the first 6 months, immediately followed by an open-label extension in which all patients will receive AZD0530 100mg once daily oral dose for a further 12 months.

Endpoints: Endpoints include objective change in heterotopic bone volume measured by low-dose whole-body computer tomography (CT) , [18F] NaF Positron Emission Tomography (PET) activity and patient reported outcome measures.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: May 6, 2025
• Est. primary completion date: May 6, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female aged 18-65 with a clinical diagnosis of FOP at screening, including congenital malformation of the great toes and a history of spontaneous or injury-induced heterotopic ossification (HO), and have a confirmed classic FOP phenotype by the documentation of an ACVR1R206H/+ or variant genomic sequence.

1. Female participants who are women of child-bearing potential will be required to use a highly effective method of contraception as defined in section 5.4, in combination with a condom or diaphragm or cervical/vault caps with spermicidal foam/gel/film/suppository), from the time of enrolment until 4 weeks after final dose of study drug, unless practicing true sexual abstinence as defined in section 5.4.

2. Male participants will be required to avoid procreative sexual intercourse with women of child-bearing potential from time of enrollment until 4 weeks after final dose of study drug through use of highly effective contraceptive methods. Male participants with a pregnant female partner will be required to use a condom for the duration of the study and for 4 weeks final dose of study drug. Male study participants will not be permitted to donate sperm for from the time of enrolment and until 4 weeks after final dose of study drug.

2. Participants will have to be able to understand and complete study and willing to sign informed consent (IC). They have to be able to attend and comply with the study visits and related activities, adhere to all study-related restrictions, and able to undergo procedures such as PET and CT imaging.

Exclusion Criteria:

1. Not willing to strictly adhere to the reproductive restrictions as defined in section 5.4

2. Women who are pregnant or breast-feeding (from the time 3 months prior to 4 weeks after completion of participation in the study)

3. The presence of significant concomitant illness or history of significant illness such as cardiac, respiratory, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, lymphatic disease, or infectious disease, that might confound the results of the study or pose additional risk to the patient;

4. Evidence of active bleeding (including hematuria or hematochezia,) acute or chronic gastrointestinal illness, inflammatory bowel disease, or mucositis

5. Malignant disease / cancer requiring treatment in the past 3 years (except some primary non melanoma skin cancer);

6. Severely impaired renal function defined as estimated glomerular filtration rate <30 mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease equation;

7. Showing uncontrolled diabetes mellitus with an HbA1C > 9%;

8. Significant viral illness or active infections at screening or randomisation; Subjects should not have subacute or acute fevers of >101 degrees F at time of screening or randomisation

9. Evidence of prolonged QT interval at screening or randomization (defined as QTc of >450 ms) .or known congenital long-QT syndrome.

10. Neutropenia defined as an absolute neutrophil count of <1,500/µl,

11. Thrombocytopenia defined as platelet count <100 × 103/µl,

12. Current blood clotting or bleeding disorder, or significantly abnormal INR-prothrombin time or partial thromboplastin time at screening, or clinically significant abnormalities in other screening laboratories, including significant abnormalities in vitamin B12 or thyroid function tests would be cause for exclusion.-

13. Abnormal liver function test results defined as aspartate aminotransferase (AST) >2.0 x upper limit of normal (ULN); alanine aminotransferase (ALT) >2.0 x ULN; and / or total bilirubin >1.5 x ULN;

14. Known allergy or intolerance to AZD0530 or any excipients used in the investigational medicinal products.

15. Simultaneous participation in another interventional clinical study or a non-interventional study with imaging measures or invasive procedures (eg. collection of blood or tissue samples); Participation in the FOP Connection Registry (www.fopconnection.org) or other studies in which patients completed study questionnaires are possible.

16. Treatment with another investigational or drug that might interfere with HO formation and the interpretation of the study drug in the last 90 days

17. Current use or history of regular alcohol consumption exceeding 14 units/week (6 glasses of 13.0% wine (175ml), 6 pints of 4.0% lager or ale (568ml), 5 pints of 4.5% cider (568 ml) or 14 glasses of 10.0% spirits (25ml)) within 6 months of screening.

18. Currently active metabolic bone disease, other than FOP.

Related Conditions & MeSH terms

• Fibrodysplasia Ossificans Progressiva

Intervention

Drug:
• AZD0530 Difumarate
AZD0530 for the duration of the trial
• Matching placebo
Matching placebo during 6 month RCT, AZD0530 thereafter

Locations

Country	Name	City	State
Germany	Klinikum Garmish-Partenkirchen	Garmisch-Partenkirchen
Netherlands	Amsterdam University Medical Center	Amsterdam
United Kingdom	Royal National Orthopaedic Hospital	London

Sponsors (7)

Lead Sponsor	Collaborator
Amsterdam UMC, location VUmc	AstraZeneca, Brigham and Women's Hospital, Innovative Medicines Initiative, Klinikum Garmisch-Patenkirchen, Royal National Orthopaedic Hospital NHS Trust, University of Oxford

Countries where clinical trial is conducted

Germany,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The objective change between the two arms measured in heterotopic bone volume measured by low-dose whole body CT over the initial 6 month RCT		Baseline, month 6
Secondary	Safety and tolerability assessments are the incidence and severity of adverse events (AE) during the RCT at the end of week 28.		Baseline, month 6 (+overall duration study)
Secondary	The change in heterotopic bone volume measured by low-dose whole body CT over six-months treatment during open-label extension of AZD0530 compared to the previous placebo arm of the RCT		Baseline, month 6, month 12
Secondary	The change in heterotopic bone volume measured by low-dose whole body CT over twelve-months treatment during open-label extension of AZD0530 compared to the historical data of Clementia (NCT02322255)		Baseline, month 6, month 12, month 18
Secondary	Change in the volume of individual HO lesions	measured by low-dose whole body CT over the initial 6 month RCT and the change over twelve-months therapy during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.	Baseline, month 6, month 12, month 18
Secondary	Change in number of HO lesions measured by CT over the initial 6 month RCT and in addition the change over twelve-months during open-label extension of AZD0530 compared to the historical data of Clementia and compared to the 6 months placebo-arm.		Baseline, month 6, month 12, month 18
Secondary	In patients with at least 1 active lesion at baseline: Change (and Area Under the Curve (AUC) analysis) of lesion activity	by 18F-NaF PET over the initial 6 month RCT and over months 6-12 compared to the 6 months RCT of the placebo arm, including change from baseline in 18F-NaF Standard Uptake Volume (SUVmean or peak) of individual active HO site	Baseline, month 6, month 12
Secondary	In patients with at least 1 active lesion at baseline: Change in number of active lesion on 18F-NaF PET from baseline to 6 and 12months		Baseline, month 6, month 12
Secondary	Change and percent change from baseline in biomarkers of bone formation levels in serum over time.	Including Total Procollagen Type 1 N-Terminal Propeptide (P1NP), Alkaline Phosphatase (AP) fasting cross-linked C-terminal telopeptide of type I colla-gen (ßCTX). Selected genetic markers for FOP activity	Baseline, week 3 through month 18
Secondary	Joint function assessment by physician at baseline and week 3, month 3,6,9,12,and18 by the cumulative analog joint involvement scale (CAJIS) and the quantitative detailed multi-joint assessment at baseline and month 6, 12 and 18		baseline, week 3, month 3,6,9,12,and 18
Secondary	Patient-reported global health status the 36-item Short Form Health Survey (SF-36) at baseline and week 3, month 3,6,9,12,and 18		baseline, week 3, month 3,6,9,12,and 18
Secondary	FOP disease activity assessed by movement disabilities and quality of life using FOP Independent Activity of Daily Living (FOP I-ADL)		baseline, week 3, month 3,6,9,12,and 18
Secondary	Number of reported flare-ups by the patient		Each day (day 0-month18)
Secondary	Pharmacokinetic measurements: blood for determination of plasma concentrations of AZD0530 (pre-dose)on the day of the study visits at 6, 12 and 18months		6,12 and 18months